ME2

Across TCGA pan-cancer cohorts, ME2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ME2 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ME2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ME2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where ME2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.599	0.293	.018	16	view →
HNSC	DFS	Tertile	All	0.917	0.328	.010	14	view →
CCRCC	DFS	Tertile	III,IV	0.822	1.000	.022	13	view →
GBM	DFS	Tertile	All	0.289	0.477	.020	5	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.726	.018	3	view →
LSCC	OS	Tertile	III,IV	0.993	0.556	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ME2–PDAC (DFS)

Open the PDAC breakdown →